Study guide

13.1 Goals of Care, Perioperative Care, and Transitions of Care

Board Certified Critical Care Pharmacist Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pathophysiology and Recognition of Critical Illness

1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness

2 Chapter 2: Medical Devices and Circulatory Support

2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care

3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management

3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation

4 Chapter 4: Vasoactive and Inotropic Therapy in Shock

4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock

5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)

5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness

6 Chapter 6: Cardiovascular Emergencies

6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias

7 Chapter 7: Pulmonary and Infectious Diseases in the ICU

7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU

8 Chapter 8: Neurocritical Care

8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury

9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies

9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy

10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition

10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral

11 Chapter 11: Quality, Safety, and Clinical Guidelines

11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions

12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine

12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management

13 Chapter 13: Treatment Planning and Care Coordination

13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education

13.1 Goals of Care, Perioperative Care, and Transitions of Care

Key Takeaways Explain This Topic AI

Goals-of-care conversations in the ICU should occur within 72 hours of admission and incorporate patient values, prognosis, and treatment-limitation decisions that directly influence pharmacotherapy choices (e.g., palliative vs. curative antibiotics).

Perioperative ICU care requires medication management across three phases: preoperative (beta-blockade, anticoagulation bridging, fasting-status meds), intraoperative (anesthesia selection, vasopressor choice), and postoperative (pain, nausea/VTE prophylaxis).

Transitions of care (admission, transfer, discharge) carry high medication error risk; structured medication reconciliation by pharmacists reduces errors by ~75% and adverse events by 30%.

Step-down transfer requires explicit communication of infusion titration parameters, anticoagulation plan, antimicrobial duration, and TPN weaning to prevent medication discontinuation errors.

Last updated: July 2026

  • Goals of Care, Perioperative Care, and Transitions of Care
  • Goals of Care (ECO 2A3)

Goals-of-care conversations align treatment intensity with patient values, prognosis, and expected outcomes. The Society of Critical Care Medicine recommends such conversations within 72 hours of ICU admission and at significant clinical changes.

Pharmacist Role in Goals of Care

  • Decision Pharmacist Contribution
  • Treatment limitation Adjust medication regimens to comfort-focused: opioids, benzodiazepines, anticholinergics

Antibiotic continuation Weigh prognosis, futility, and patient preference; palliative antibiotic use may focus on symptom relief rather than cure

Anticoagulation Continue for VTE/AFib prophylaxis unless bleeding risk prohibitive; deprescribe when prognosis <2 weeks

Artificial nutrition Reassess after 7-10 days if not improving; risk of aspiration vs. benefit

Statin discontinuation STOP-STAT RCT: continuation in critical illness offered no mortality benefit; deprescribe when prognosis is poor

  • Steroid continuation Continue physiologic doses; avoid high-dose without indication
  • Decision Aids and Documentation

POLST (Physician Orders for Life-Sustaining Treatment): portable medical orders following patient across care settings.

Advance directives: patient-prepared documents.

Code status documentation: in EHR and visible to all clinicians.

Family meeting facilitation: pharmacist participation improves deprescribing and antibiotic stewardship.

  • Perioperative Care (ECO 2A4)
  • Preoperative ICU Optimization
  • Chronic Medication Pre-op Decision
  • Beta-blockers Continue (DECREASE trials); avoid initiation within 24h of surgery (risk of stroke/hypotension)
  • Statins Continue; consider initiating in vascular surgery (POISE-2 trial evidence)
  • ACE inhibitors/ARBs Hold morning of surgery (hypotension risk)
  • Diuretics Hold morning of surgery
  • Insulin Continue basal at 75-80% of usual; hold rapid-acting
  • Antiplatelets Continue for recent PCI (BMS <3 months, DES <6 months); hold for elective non-cardiac surgery
  • DOACs Hold 24-48h (apixaban) to 48-72h (rivaroxaban) per renal function and bleeding risk
  • Warfarin Bridge with heparin if high VTE/TE risk; stop 5 days pre-op, target INR <1.5
  • Levothyroxine Continue morning of surgery with sip of water
  • Corticosteroids Continue; stress-dose hydrocortisone 100 mg IV q8h if chronic daily dose >20mg for >3 weeks
  • Intraoperative Considerations

Anesthesia depth: BIS monitoring; avoid over-sedation in elderly (post-op delirium risk).

Vasopressor selection: phenylephrine for SVT; norepinephrine for septic shock intraoperative; vasopressin for vasoplegia.

Antifibrinolytics: TXA 1 g IV at incision and 1 g at 3 hours in cardiac and major orthopedic surgery reduces bleeding.

Antibiotic prophylaxis: repeat dose if surgery >4 hours or blood loss >1500 mL.

Postoperative ICU Care

Pain: multimodal — acetaminophen, regional/neuraxial, ketamine adjunct, opioid sparing.

PONV: ondansetron + dexamethasone + haloperidol triple therapy for high-risk.

VTE prophylaxis: start 12-24h post-op per surgical service; enoxaparin preferred over UFH in surgical patients (meta-analyses).

Delirium prevention: minimize benzodiazepines; orient patient; early mobilization.

Glycemic control: target 140-180 mg/dL; avoid hyperglycemia and hypoglycemia.

Stress ulcer prophylaxis: only if mechanically ventilated >48h or coagulopathy.

  • Transitions of Care (ECO 2A5)
  • Three Critical Transition Points

Admission to ICU: reconcile outpatient, ED, and pre-admission medications; identify held meds, new allergies, anticoagulation status, controlled substances.

ICU to step-down or floor transfer: explicit transfer orders including titration parameters, anticoagulation plan, antibiotic duration, TPN weaning, and oxygen weaning plan.

Discharge to home/SNF: medication list reconciliation, deprescribing, patient education, follow-up appointments, post-ICU clinic referral.

Pharmacist-Led Reconciliation

Pharmacist-led reconciliation reduces medication errors by 75-90% (multiple meta-analyses):

  • Component Action
  • Collect Home med list from EHR, pharmacy fill records, family interview
  • Compare Each home med vs. current orders: continue, hold, modify, stop
  • Communicate Document changes with rationale; alert team of held meds needing resumption
  • Counsel Patient and family at discharge with teach-back
  • Follow-up Phone call within 48-72h post-discharge reduces readmission
  • High-Risk Medications at Transitions

Anticoagulants: wrong dose, double coverage, missed bridge.

Insulin: sliding scale alone insufficient; basal/bolus correction required.

Opioids: duplicate prescriptions from hospital and outpatient prescribers.

Antibiotics: incomplete duration documentation leads to premature discontinuation.

Immunosuppressants: wrong dose in transplant handoffs.

Antiretrovirals: interactions with new meds, missed doses.

Antiepileptics: dose changes with initiation/discontinuation of interacting meds.

Medication Reconciliation Tools

MedRec forms: structured collection sheets.

EHR reconciliation modules: with drop-downs for actions.

Pharmacy fill history: from pharmacy benefit manager or state PDMP.

Discrepancy documentation: flag unresolved discrepancies at each transition.

Clinical Scenario

A 68-year-old with HFrEF (EF 30%), CKD 3 (CrCl 35), AFib on apixaban, and T2DM is admitted post-emergency cholecystectomy for gangrenous cholecystitis. Post-op course complicated by AKI (CrCl 25). Pre-ICU meds: apixaban 5 mg BID, carvedilol 12.5 mg BID, lisinopril 10 mg daily, furosemide 40 mg daily, empagliflozin 10 mg daily, insulin glargine 20 units nightly. What is the appropriate transition plan?

Answer: Hold apixaban (AKI + post-op bleeding risk); start VTE prophylaxis with enoxaparin 30 mg SC daily (CrCl 25, post-op). Hold lisinopril and empagliflozin (AKI, hypotension risk). Continue carvedilol (avoid withdrawal) and furosemide (may need increase if volume overload). Convert insulin glargine to IV insulin infusion or continue at 75% dose with correctional rapid-acting protocol, target 140-180 mg/dL. Document all changes with rationale; resume held meds as renal function and clinical status normalize.